Published in Am J Pathol on February 04, 2012
Signaling mechanisms in mammalian myoblast fusion. Sci Signal (2013) 1.15
Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle (2013) 1.03
The TWEAK-Fn14 system as a potential drug target. Br J Pharmacol (2013) 0.96
Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol (2015) 0.94
Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol (2014) 0.90
The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease. Cytokine Growth Factor Rev (2013) 0.85
Emerging therapeutic options for sporadic inclusion body myositis. Ther Clin Risk Manag (2015) 0.79
Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies. Int J Mol Sci (2015) 0.79
TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy. Hum Mol Genet (2014) 0.77
TWEAK Regulates Muscle Functions in a Mouse Model of RNA Toxicity. PLoS One (2016) 0.75
Expression of tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 in patients with polymyositis and dermatomyositis. Arthritis Res Ther (2014) 0.75
Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J (2007) 1.92
Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol (2004) 1.77
Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy. J Am Coll Cardiol (2003) 1.72
Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment. Am J Physiol Cell Physiol (2005) 1.26
CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol (2010) 1.16
pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J Neurosci Res (2006) 1.15
Novel GNE mutations in Italian families with autosomal recessive hereditary inclusion-body myopathy. Hum Mutat (2004) 1.14
MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Proc Natl Acad Sci U S A (2006) 1.11
Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord (2004) 1.08
Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol (2003) 1.06
The ER-bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis. PLoS One (2008) 1.05
Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies. Stem Cells (2007) 1.02
The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol (2004) 1.01
IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine (2008) 1.01
Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS One (2012) 1.00
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. J Neurol (2013) 0.99
An Italian family with inclusion-body myopathy and frontotemporal dementia due to mutation in the VCP gene. Muscle Nerve (2008) 0.98
Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Hum Mol Genet (2013) 0.97
The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. J Neuroimmunol (2007) 0.96
Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol (2005) 0.95
Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients. J Neuropathol Exp Neurol (2013) 0.95
Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle. J Neurochem (2007) 0.93
Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis. J Neurochem (2006) 0.91
Hereditary inclusion-body myopathy: clues on pathogenesis and possible therapy. Muscle Nerve (2009) 0.91
Muscle imaging findings in GNE myopathy. J Neurol (2012) 0.90
Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients. J Clin Immunol (2004) 0.88
Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. Hum Immunol (2008) 0.88
alpha-Dystroglycan does not play a major pathogenic role in autosomal recessive hereditary inclusion-body myopathy. Neuromuscul Disord (2004) 0.87
Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin Immunol (2007) 0.86
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. J Neuroimmunol (2013) 0.85
Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci (2011) 0.85
Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients. Immunology (2008) 0.85
Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma. J Neuroimmunol (2013) 0.84
Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol Aging (2008) 0.84
Invited review: Stem cells and muscle diseases: advances in cell therapy strategies. Neuropathol Appl Neurobiol (2015) 0.83
Insulin-like growth factor I in inclusion-body myositis and human muscle cultures. J Neuropathol Exp Neurol (2004) 0.83
An Italian case of hereditary myopathy with early respiratory failure (HMERF) not associated with the titin kinase domain R279W mutation. Neuromuscul Disord (2010) 0.83
Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab. Eur Neurol (2014) 0.83
Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis. Peptides (2005) 0.82
Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion. Neuroimmunomodulation (2013) 0.81
Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy. Dis Markers (2005) 0.81
Mesoangioblasts from facioscapulohumeral muscular dystrophy display in vivo a variable myogenic ability predictable by their in vitro behavior. Cell Transplant (2010) 0.80
Vessel-associated stem cells from skeletal muscle: From biology to future uses in cell therapy. World J Stem Cells (2010) 0.79
Multi-organ investigation in 16 CADASIL families from central Italy sharing the same R1006C mutation. Neurosci Lett (2011) 0.79
Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis. Clin Neurophysiol (2013) 0.78
The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. J Neuroimmunol (2008) 0.78
Cerebellar degeneration and ocular myasthenia gravis in a patient with recurring ovarian carcinoma. Neurol Sci (2009) 0.78
Pathogenic role of mtDNA duplications in mitochondrial diseases associated with mtDNA deletions. Am J Med Genet A (2003) 0.78
Progressive multifocal leukoencephalopathy in a patient with Franklin disease and hypogammaglobulinemia. J Neurol Sci (2009) 0.77
Bilateral thalamic stroke transiently reduces arousals and NREM sleep instability. J Neurol Sci (2010) 0.76
A human anti-neuronal autoantibody against GABA B receptor induces experimental autoimmune agrypnia. Exp Neurol (2007) 0.76
In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients. Neuroimmunomodulation (2006) 0.76
Integrated backscatter in Becker muscular dystrophy patients with functionally normal heart: myocardial ultrasound tissue characterization study. J Am Coll Cardiol (2006) 0.76
Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2). Exp Mol Pathol (2010) 0.76
Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies. Neuromuscul Disord (2011) 0.76